# LB Pharmaceuticals (LBRX) — Analyst Forecast

LBRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lbrx/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 11 | 1 | 0 | 12 |

## Price target

| Low | Average | High | Analysts |
| --- | --- | --- | --- |
| $35.00 | $60.33 | $80.00 | 6 |

Last price $36.69 (as of Oct 16, 2026).

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Oct 9, 2026 | Canaccord Genuity | Initiated Coverage | Buy | $65.00 |
| Oct 6, 2026 | Guggenheim | Initiated Coverage | Buy | $80.00 |
| Oct 5, 2026 | Roth Capital | Downgraded | Buy → Neutral | $35.00 |
| Oct 2, 2026 | Needham | Initiated Coverage | Buy | $68.00 |
| Aug 24, 2026 | HC Wainwright & Co. | Maintained | Buy | $60.00 |
| Aug 12, 2026 | BMO Capital | Maintained | Outperform | $54.00 |
| Aug 3, 2026 | HC Wainwright & Co. | Maintained | Buy | $45.00 |
| Jul 21, 2026 | BMO Capital | Initiated Coverage | Outperform | $46.00 |
| Jul 7, 2026 | Wolfe Research | Initiated Coverage | Outperform | $45.00 |
| Apr 27, 2026 | HC Wainwright & Co. | Initiated Coverage | Buy | $45.00 |
| Apr 10, 2026 | Craig-Hallum | Initiated Coverage | Buy | $36.00 |
| Mar 27, 2026 | Stifel | Maintained | Buy | $40.00 |
| Dec 11, 2025 | Stifel | Maintained | Buy | $35.00 |
| Oct 6, 2025 | Piper Sandler | Initiated Coverage | Overweight | $78.00 |
| Oct 6, 2025 | Leerink Partners | Initiated Coverage | Outperform | $34.00 |
| Oct 6, 2025 | Stifel | Initiated Coverage | Buy | $27.00 |

## Frequently Asked Questions

### What is the price target for LBRX stock?

The average 12-month analyst price target for LB Pharmaceuticals (LBRX) is $60.33, with a high estimate of $80.00 and a low of $35.00, across 6 analysts.

### Is LBRX a buy, sell, or hold?

Analysts covering LB Pharmaceuticals currently average a Buy rating: 11 buy, 1 hold and 0 sell, from 12 analysts. Ratings reflect analyst opinion, not investment advice.

### What upside do analysts see for LBRX?

The average price target of $60.33 implies 64.44% upside from the last price of $36.69.

### What is the latest analyst rating on LBRX?

On Oct 9, 2026, Canaccord Genuity initiated coverage of LB Pharmaceuticals at Buy with a price target of $65.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).